Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.274,05 -131,61 (-0,34%) EUR/USD
1,0717 -0,0001 (-0,01%) Bitcoin EUR
54.017,30 -2.472,72 (-4,38%) CMC Crypto 200
1.271,33 -67,74 (-5,06%)
Vistin Pharma ASA (0RAM.L)
- GlobeNewswire
Vistin Pharma ASA: Second quarter and first half 2023 financial results
Oslo, Norway, 23rd of August 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter and first half of 2023. Revenue in the second quarter ended at MNOK 107 compared to MNOK 69 in Q2 2022. Increased volume from the new production line compared to the same quarter last year has resulted in more volumes available for sale. Revenue for first half of 2023 ended at MNOK 208 compared to MNOK 102 YTD last year, a 103% increase. Second quarter EBI
- GlobeNewswire
Vistin Pharma ASA: Invitation to Q2 2023 conference call
Oslo, Norway, 16 August 2023 Vistin Pharma ASA will release its second quarter and YTD 2023 results on Wednesday 23rd of August 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 23rd of August at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The second quarter conference call will be available via web and audio through the following access points: Webcas
- GlobeNewswire
Management in Vistin Pharma ASA purchases shares
4 July 2023: Vistin Pharma ASA (the “Company”) has on 4 July 2023 sold shares to members of its management team for its long-term incentive plan (LTIP), as approved by the general meeting on the 22 May 2023, at a price of NOK 23,00 per share (the “Purchase Price”). The following persons discharging managerial responsibilities (primary insiders) have purchased shares: Kjell-Erik Nordby (CEO): 40 000 shares, each at a price equal to the Purchase PriceAfter this transaction, Kjell-Erik Nordby owns
